Price Target Changed • Nov 16
Price target decreased to US$18.00 Down from US$70.50, the current price target is provided by 1 analyst. New target price is 177% above last closing price of US$6.50. Stock is down 65% over the past year. The company is forecast to post a net loss per share of US$12.15 next year compared to a net loss per share of US$9.88 last year. Reported Earnings • Nov 16
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Third quarter 2022 results: US$3.00 loss per share (further deteriorated from US$2.79 loss in 3Q 2021). Net loss: US$8.23m (loss widened 9.2% from 3Q 2021). Revenue missed analyst estimates by 8.9%. Earnings per share (EPS) also missed analyst estimates by 6.4%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Norman Radow was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Aug 25
Independent Director recently bought US$76k worth of stock On the 19th of August, Douglas Janzen bought around 10k shares on-market at roughly US$7.63 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$257k more in shares than they have sold in the last 12 months. Reported Earnings • Aug 12
Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2022 results: US$3.29 loss per share (up from US$3.35 loss in 2Q 2021). Net loss: US$8.98m (flat on 2Q 2021). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) missed analyst estimates by 39%. Over the next year, revenue is forecast to grow 309%, compared to a 6.4% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings. Reported Earnings • May 13
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: US$3.75 loss per share (down from US$1.11 loss in 1Q 2021). Net loss: US$10.2m (loss widened 369% from 1Q 2021). Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 200%. Over the next year, revenue is forecast to grow 425%, compared to a 8.8% growth forecast for the industry in the US. Price Target Changed • Apr 27
Price target increased to US$5.00 Up from US$3.59, the current price target is provided by 1 analyst. New target price is 1,329% above last closing price of US$0.35. Stock is down 64% over the past year. The company is forecast to post a net loss per share of US$0.20 next year compared to a net loss per share of US$0.40 last year. Reported Earnings • Mar 13
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: US$0.40 loss per share (up from US$1.72 loss in FY 2020). Net loss: US$24.9m (loss narrowed 13% from FY 2020). Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 2.4%. Over the next year, revenue is forecast to grow 212%, compared to a 10% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 135% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings. Recent Insider Transactions • Dec 15
Chief Operating Officer recently bought US$79k worth of stock On the 9th of December, William Little bought around 150k shares on-market at roughly US$0.53 per share. This was the largest purchase by an insider in the last 3 months. This was William's only on-market trade for the last 12 months. Reported Earnings • Nov 12
Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.51 loss in 3Q 2020) Third quarter 2021 results: Net loss: US$7.54m (loss narrowed 26% from 3Q 2020). Recent Insider Transactions • Aug 21
Independent Director recently bought US$76k worth of stock On the 19th of August, Douglas Janzen bought around 100k shares on-market at roughly US$0.76 per share. In the last 3 months, they made an even bigger purchase worth US$94k. Insiders have collectively bought US$305k more in shares than they have sold in the last 12 months. Reported Earnings • Aug 12
Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.81 loss in 2Q 2020) Second quarter 2021 results: Net loss: US$9.03m (loss narrowed 9.0% from 2Q 2020). Price Target Changed • Jul 03
Price target increased to US$5.00 Up from US$3.59, the current price target is an average from 2 analysts. New target price is 462% above last closing price of US$0.89. Stock is down 63% over the past year. Recent Insider Transactions • Jun 24
Independent Director recently bought US$87k worth of stock On the 22nd of June, Douglas Janzen bought around 100k shares on-market at roughly US$0.87 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$136k more in shares than they have sold in the last 12 months. Reported Earnings • May 09
First quarter 2021 earnings released: US$0.04 loss per share (vs US$0.38 loss in 1Q 2020) First quarter 2021 results: Net loss: US$2.17m (loss narrowed 47% from 1Q 2020). Reported Earnings • Mar 14
Full year 2020 earnings released: US$1.72 loss per share (vs US$5.40 loss in FY 2019) The company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: US$1.96m (down 6.4% from FY 2019). Net loss: US$28.7m (loss narrowed 18% from FY 2019). Over the last 3 years on average, earnings per share has increased by 129% per year but the company’s share price has fallen by 78% per year, which means it is significantly lagging earnings. Analyst Estimate Surprise Post Earnings • Mar 14
Revenue and earnings miss expectations Revenue missed analyst estimates by 2.4%. Earnings per share (EPS) also missed analyst estimates by 9.6%. Over the next year, revenue is forecast to grow 136%, compared to a 21% growth forecast for the Medical Equipment industry in the US. Is New 90 Day High Low • Jan 27
New 90-day high: US$1.36 The company is up 28% from its price of US$1.06 on 28 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$19.91 per share. Is New 90 Day High Low • Dec 09
New 90-day low: US$0.72 The company is down 67% from its price of US$2.17 on 09 September 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Nov 13
New 90-day low: US$0.75 The company is down 66% from its price of US$2.17 on 14 August 2020. The American market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Analyst Estimate Surprise Post Earnings • Nov 08
Revenue beats expectations, earnings disappoint Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) missed analyst estimates by 3.8%. Over the next year, revenue is forecast to grow 225%, compared to a 16% growth forecast for the Medical Equipment industry in the US. Reported Earnings • Nov 08
Third quarter 2020 earnings released: US$0.51 loss per share The company reported a soft third quarter result with increased losses and weaker control over expenses, although revenues were improved. Third quarter 2020 results: Revenue: US$626.4k (up 25% from 3Q 2019). Net loss: US$10.2m (loss widened 65% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 91% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Oct 24
New 90-day low: US$2.03 The company is down 22% from its price of US$2.60 on 24 July 2020. The American market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. 
